268 related articles for article (PubMed ID: 10725870)
1. Regulation of the expression of MHC class I and II by class II transactivator (CIITA) in hematopoietic cells.
Liu A; Takahashi M; Toba K; Zheng Z; Hashimoto S; Nikkuni K; Furukawa T; Koike T; Aizawa Y
Hematol Oncol; 1999 Dec; 17(4):149-60. PubMed ID: 10725870
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-gamma in haematopoietic tumour cells.
Morimoto Y; Toyota M; Satoh A; Murai M; Mita H; Suzuki H; Takamura Y; Ikeda H; Ishida T; Sato N; Tokino T; Imai K
Br J Cancer; 2004 Feb; 90(4):844-52. PubMed ID: 14970863
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylation, but not hypermethylation, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas.
Kanaseki T; Ikeda H; Takamura Y; Toyota M; Hirohashi Y; Tokino T; Himi T; Sato N
J Immunol; 2003 May; 170(10):4980-5. PubMed ID: 12734341
[TBL] [Abstract][Full Text] [Related]
4. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma.
Lu HT; Riley JL; Babcock GT; Huston M; Stark GR; Boss JM; Ransohoff RM
J Exp Med; 1995 Nov; 182(5):1517-25. PubMed ID: 7595221
[TBL] [Abstract][Full Text] [Related]
5. Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines.
Rodríguez T; Méndez R; Del Campo A; Aptsiauri N; Martín J; Orozco G; Pawelec G; Schadendorf D; Ruiz-Cabello F; Garrido F
Immunogenetics; 2007 Feb; 59(2):123-33. PubMed ID: 17180681
[TBL] [Abstract][Full Text] [Related]
6. [Major histocompatibility complex class II transactivator (CIITA) hammer- head ribozyme transfer inhibits major histocompatibility complex class II (MHC-II) expression in Jukart cells].
Guo R; Zou P; Song YP; Ma J; Lu HZ; Cao YL; Tong YJ
Zhonghua Er Ke Za Zhi; 2003 Dec; 41(12):925-8. PubMed ID: 14723817
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells.
Satoh A; Toyota M; Ikeda H; Morimoto Y; Akino K; Mita H; Suzuki H; Sasaki Y; Kanaseki T; Takamura Y; Soejima H; Urano T; Yanagihara K; Endo T; Hinoda Y; Fujita M; Hosokawa M; Sato N; Tokino T; Imai K
Oncogene; 2004 Nov; 23(55):8876-86. PubMed ID: 15467734
[TBL] [Abstract][Full Text] [Related]
8. Interferon-gamma induces major histocompatibility class II transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation by human aortic smooth muscle cells.
Butticè G; Miller J; Wang L; Smith BD
Circ Res; 2006 Mar; 98(4):472-9. PubMed ID: 16439692
[TBL] [Abstract][Full Text] [Related]
9. IFN-gamma inducibility of class II transactivator is specifically lacking in human tumour lines: relevance to retinoblastoma protein rescue of IFN-gamma inducibility of the HLA class II genes.
Lu Y; Tschickardt ME; Schmidt BJ; Blanck G
Immunol Cell Biol; 1997 Aug; 75(4):325-32. PubMed ID: 9315472
[TBL] [Abstract][Full Text] [Related]
10. Lack of IFN-gamma-mediated induction of the class II transactivator (CIITA) through promoter methylation is predominantly found in developmental tumor cell lines.
van der Stoep N; Biesta P; Quinten E; van den Elsen PJ
Int J Cancer; 2002 Feb; 97(4):501-7. PubMed ID: 11802213
[TBL] [Abstract][Full Text] [Related]
11. Major histocompatibility class II HLA-DR alpha gene expression in thyrocytes: counter regulation by the class II transactivator and the thyroid Y box protein.
Montani V; Taniguchi SI; Shong M; Suzuki K; Ohmori M; Giuliani C; Napolitano G; Saji M; Fiorentino B; Reimold AM; Ting JP; Kohn LD; Singer DS
Endocrinology; 1998 Jan; 139(1):280-9. PubMed ID: 9421426
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional control of MHC genes in fetal trophoblast cells.
van den Elsen PJ; Gobin SJ; van der Stoep N; Datema G; Viëtor HE
J Reprod Immunol; 2001; 52(1-2):129-45. PubMed ID: 11600183
[TBL] [Abstract][Full Text] [Related]
13. Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL).
Cycon KA; Rimsza LM; Murphy SP
Exp Hematol; 2009 Feb; 37(2):184-194. PubMed ID: 19081173
[TBL] [Abstract][Full Text] [Related]
14. HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: acquisition of antigen processing and presentation capacity.
Sartoris S; Valle MT; Barbaro AL; Tosi G; Cestari T; D'Agostino A; Megiovanni AM; Manca F; Accolla RS
J Immunol; 1998 Jul; 161(2):814-20. PubMed ID: 9670958
[TBL] [Abstract][Full Text] [Related]
15. Molecular analysis of G1B and G3A IFN gamma mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii gene induction.
Chin KC; Mao C; Skinner C; Riley JL; Wright KL; Moreno CS; Stark GR; Boss JM; Ting JP
Immunity; 1994 Nov; 1(8):687-97. PubMed ID: 7600294
[TBL] [Abstract][Full Text] [Related]
16. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.
Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y
J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758
[TBL] [Abstract][Full Text] [Related]
17. CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells.
Meissner M; Whiteside TL; Kaufmann R; Seliger B
Arch Dermatol Res; 2009 Feb; 301(2):189-93. PubMed ID: 19104823
[TBL] [Abstract][Full Text] [Related]
18. [The expression and significance of major histocompatibility complex II transactivator gene in five human malignant hematological cell lines].
You Y; Zou P; Guo R
Zhonghua Nei Ke Za Zhi; 2004 Apr; 43(4):288-91. PubMed ID: 15130416
[TBL] [Abstract][Full Text] [Related]
19. CIITA-dependent and -independent class II MHC expression revealed by a dominant negative mutant.
Zhou H; Su HS; Zhang X; Douhan J; Glimcher LH
J Immunol; 1997 May; 158(10):4741-9. PubMed ID: 9144488
[TBL] [Abstract][Full Text] [Related]
20. The two novel MHC class II transactivators RFX5 and CIITA both control expression of HLA-DM genes.
Kern I; Steimle V; Siegrist CA; Mach B
Int Immunol; 1995 Aug; 7(8):1295-9. PubMed ID: 7495736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]